Monkey . | Spleen . | Mesenteric lymph node . | PBL . | ||||||
---|---|---|---|---|---|---|---|---|---|
Fresh . | p11C, C-M*expanded . | Fresh . | p11C, C-M expanded . | Fresh . | p11C, C-M expanded . | ||||
% tetramer . | % tetramer . | % lysis (5/3/1)† . | % tetramer . | % tetramer . | % lysis (5/3/1) . | % tetramer . | % tetramer . | % lysis (5/3/1) . | |
575 | 8.7‡ | 8.32-153 | 29/21/152-153 | 2.7 | 28.8 | 34/25/15 | 5.3 | 18.3 | 14/9/5 |
3KI | 3.0 | 49.0 | 55/50/40 | 2.8 | 43.9 | 57/51/40 | 1.3 | 61.3 | 67/67/60 |
IPI | 9.4 | 49.8 | 55/54/36 | 7.7 | 69.5 | 58/52/46 | 6.0 | 69.5 | 55/53/45 |
297 | 11.7 | 19.5 | 18/12/6 | 6.2 | 6.5 | 18/14/7 | 6.2 | 50.3 | 51/42/31 |
Monkey . | Spleen . | Mesenteric lymph node . | PBL . | ||||||
---|---|---|---|---|---|---|---|---|---|
Fresh . | p11C, C-M*expanded . | Fresh . | p11C, C-M expanded . | Fresh . | p11C, C-M expanded . | ||||
% tetramer . | % tetramer . | % lysis (5/3/1)† . | % tetramer . | % tetramer . | % lysis (5/3/1) . | % tetramer . | % tetramer . | % lysis (5/3/1) . | |
575 | 8.7‡ | 8.32-153 | 29/21/152-153 | 2.7 | 28.8 | 34/25/15 | 5.3 | 18.3 | 14/9/5 |
3KI | 3.0 | 49.0 | 55/50/40 | 2.8 | 43.9 | 57/51/40 | 1.3 | 61.3 | 67/67/60 |
IPI | 9.4 | 49.8 | 55/54/36 | 7.7 | 69.5 | 58/52/46 | 6.0 | 69.5 | 55/53/45 |
297 | 11.7 | 19.5 | 18/12/6 | 6.2 | 6.5 | 18/14/7 | 6.2 | 50.3 | 51/42/31 |
p11C, C-M represents the 9-amino acid fragment optimal epitope of the SIV Gag 12-amino acid peptide p11C.
E:T ratios.
Percent staining of tetrameric Mamu-A*01/p11C, C-M complex on CD8+ T cells. CD8+ T cells are defined by gating on CD8αβ+ CD3+ cells.
Percent p11C, C-M-specific lysis was calculated as percent specific release by p11C, C-M-pulsed Mamu-A*01+ target cells minus the percent specific release by control peptide p11B-pulsedMamu-A*01+ target cells.